Short-acting opioid (heroin, oxycodone) withdrawal begins 6–24 hours after last use, peaks at 36–72 hours, and largely resolves in 5–7 days. Long-acting opioids (methadone) take longer, onset 24–48 hours, resolution 2–3 weeks. Post-Acute Withdrawal Syndrome (PAWS), mood instability, cravings, sleep disruption, can persist for 3–12 months. MAT (buprenorphine, methadone) eliminates acute withdrawal while reducing overdose mortality by 50%+.
Opioid withdrawal is rarely fatal, but relapse is. Tolerance drops dramatically within days of stopping. Returning to a previous "normal" dose after even a few days of abstinence can cause fatal overdose. This is why the period immediately following detox carries the highest overdose mortality risk. Medication-assisted treatment (MAT) directly addresses this. Call SAMHSA at 1-800-662-4357 to find local treatment.
Why Opioid Withdrawal Happens: The Receptor Science
Opioids bind to mu-opioid receptors throughout the brain and body. With chronic use, receptors downregulate, the brain reduces sensitivity to compensate for constant activation. When opioids are removed, these receptors are suddenly understimulated. The locus coeruleus (the brain's primary norepinephrine center, which regulates arousal, anxiety, and heart rate) goes into overdrive. This produces most of the acute withdrawal symptoms: anxiety, sweating, racing heart, and muscle cramping.
Simultaneously, dopamine systems, suppressed during active use, remain blunted, producing dysphoria, anhedonia, and profound motivational deficits that persist well beyond acute withdrawal as PAWS.
The Timeline: Short-Acting Opioids
Short-acting opioids include heroin, oxycodone (OxyContin), hydrocodone (Vicodin), morphine, and codeine. These have half-lives of 4–8 hours, producing a faster and more intense withdrawal curve.
First Symptoms Appear
Anxiety and restlessness emerge first, a feeling of being in your own skin wrong. Yawning, watery eyes, runny nose, and mild sweating begin. These are primarily driven by the locus coeruleus activating. Many people describe this stage as feeling like "the worst flu coming on." Cravings are intense from the beginning.
Symptoms Escalate
Muscle aches and bone pain develop, "like your bones are breaking" is a common description, reflecting hyperalgesia from opioid receptor rebound. Goosebumps (piloerection, which gives withdrawal its street name "cold turkey") appear. Nausea begins, along with abdominal cramping. Insomnia becomes severe, the restless leg sensation makes lying still nearly impossible. COWS score typically reaches moderate range.
Acute Peak, The Hardest Days
Peak intensity. Vomiting and diarrhea are common and can cause dangerous dehydration, staying hydrated is critical. Vital sign abnormalities: elevated pulse (often 100–120 bpm), hypertension, and temperature dysregulation (alternating hot flashes and chills). Dilated pupils. Extreme restlessness (akathisia). For most people quitting cold turkey, these 72 hours are the hardest they'll experience. COWS often 25+.
Intensity Begins Easing
Physical symptoms start to plateau and slowly decrease. Vomiting typically resolves first, followed by muscle cramps. Sweating and insomnia persist. Energy remains very low, profound fatigue sets in as the body begins repair. Appetite begins returning in some people. Cravings remain severe throughout this phase, making relapse risk extremely high.
Acute Resolution
Most physical symptoms resolve. Lingering symptoms: mild sleep disruption, irritability, low energy, and anxiety. The body has cleared opioids but neurological recalibration is still in early stages. Most people report "feeling almost human again" around day 7-10, though mood remains fragile. The biggest risk here is feeling better and underestimating ongoing recovery needs.
Post-Acute Withdrawal Begins
Sleep quality often worsens again as acute fatigue resolves and insomnia becomes more prominent. Dysphoria and anhedonia, difficulty feeling pleasure, low motivation, emotional flatness, emerge as the dominant symptoms. Anxiety, irritability, and difficulty concentrating persist. Intense cravings can still appear triggered by stress, environments, or sensory cues. This phase catches many people off guard after the relief of clearing acute withdrawal.
PAWS Continuation
Symptoms wax and wane rather than steadily improving. Good days and bad days alternate unpredictably. Mood instability, anxiety spikes, and occasional intense cravings remain. Dopamine system function is gradually recovering, reward sensitivity for everyday activities begins returning. Sleep begins improving for most people. Ongoing support (MAT, counseling, peer support) significantly improves outcomes during this window.
Neurological Recovery
Opioid receptor density recovers significantly over this period. Emotional regulation improves. Sleep normalizes for most people. Cravings become less frequent and intense. They still occur but are more manageable. Motivation and the ability to feel pleasure return. Research shows quality of life markers improve dramatically by the 12-month mark for people in sustained recovery. Many people report feeling better than they have in years.
Long-Acting Opioids: A Different Timeline
Long-acting opioids, particularly methadone (half-life 24–36 hours) and extended-release oxymorphone or oxycodone, produce a delayed, more prolonged withdrawal curve. Buprenorphine (partial agonist, long half-life) is itself used in MAT, so "withdrawal from buprenorphine" is a specific situation that requires medical management.
Methadone Withdrawal: A Different Beast
Onset: 24–48 hours after last dose (sometimes longer, due to the long half-life)
Peak: Days 3–8, symptoms are typically less intense than short-acting opioid withdrawal but last significantly longer
Duration: 2–3 weeks of significant symptoms, with lingering effects up to 4–6 weeks
The prolonged course makes cold-turkey methadone withdrawal particularly challenging. Medically supervised taper or transition to buprenorphine is strongly preferred over abrupt cessation.
The COWS Scale: How Clinicians Measure Withdrawal
The Clinical Opiate Withdrawal Scale (COWS) is the standard clinical tool for assessing withdrawal severity and timing MAT initiation. It measures 11 signs over a structured assessment. Understanding it helps you communicate with providers.
Clinicians typically initiate buprenorphine when COWS reaches 8–12, mild-to-moderate withdrawal. Starting too early (before enough opioids have cleared) can precipitate severe withdrawal. This is why "starting Suboxone too soon" is a known risk that needs medical guidance.
PAWS: Post-Acute Withdrawal Syndrome
PAWS is the leading driver of late relapse. Many people clear acute withdrawal successfully but relapse weeks or months later when PAWS symptoms become overwhelming. Understanding it matters.
Dysphoria & Anhedonia
Inability to feel pleasure. Everyday activities feel flat. Driven by dopamine receptor desensitization that takes months to reverse.
Sleep Disruption
Difficulty falling and staying asleep. Vivid or disturbing dreams. Often the last symptom to resolve, can persist 3–6 months.
Cognitive Fog
Memory problems, difficulty concentrating, slow processing. Prefrontal cortex function recovers gradually over months.
Anxiety Spikes
Episodic anxiety attacks, often triggered by stress or opioid-associated cues. Hyperactive norepinephrine system recalibrating.
Mood Instability
Emotional swings, irritability, periodic depression. Serotonin and dopamine systems both affected during chronic opioid use.
Cravings
Intense, episodic cravings triggered by stress, environmental cues, or random memory activation. A core PAWS feature that MAT significantly reduces.
Medication-Assisted Treatment (MAT)
MAT isn't a crutch or "trading one addiction for another", it's evidence-based medicine that reduces overdose mortality by 50%+ and dramatically improves long-term recovery outcomes. SAMHSA, the American Society of Addiction Medicine, and the CDC all recommend MAT as first-line treatment for opioid use disorder.
Buprenorphine (Suboxone)
Partial mu-opioid agonist. Eliminates withdrawal and cravings without producing a significant high (ceiling effect). Office-based prescription. No clinic required. First-line for most patients. Suboxone = buprenorphine + naloxone (prevents injection misuse).
Methadone
Long-acting full agonist. Most effective for severe OUD and patients who don't respond to buprenorphine. Dispensed through licensed OTP clinics (daily pickup initially). Highly regulated but highly effective, reduces overdose risk even more than buprenorphine in some studies.
Naltrexone (Vivitrol)
Monthly injection that fully blocks opioid receptors. No physical dependence risk. Requires complete detox first (7–10 days for short-acting, 10–14 for methadone). Best for motivated patients with strong social support. No craving suppression, pure blocking.
What to Expect: Self-Assessment Checklist
Use this to track your withdrawal and know when to seek additional support.
- I'm aware that tolerance drops rapidly and a previous dose can now cause overdose
- I have a plan if cravings become unmanageable (someone to call, a meeting to go to)
- I'm staying hydrated even when nausea makes it difficult
- I've called SAMHSA (1-800-662-4357) or a local provider to discuss MAT options
- I understand that PAWS can last months and have planned for ongoing support
- I've identified my personal high-risk triggers (places, people, emotional states)
- I know that feeling better after week 1 doesn't mean recovery is over
- I have naloxone (Narcan) accessible in case of relapse. It saves lives
Emergency & Treatment Resources
Frequently Asked Questions
See how much money you've saved by quitting:
Calculate Your Savings → · How long have you been sober? →What happens in the first 24 hours after stopping opioids?
The first 24 hours after stopping opioids mark the beginning of withdrawal, with the onset and intensity depending critically on which opioid was being used. Short-acting opioids (heroin, oxycodone, hydrocodone): half-life of 4-8 hours, withdrawal typically begins 8-12 hours after the last dose, and symptoms can be significant within the first 24 hours. Long-acting opioids (methadone, buprenorphine, extended-release oxymorphone): half-lives of 24-36+ hours, withdrawal begins 24-48 hours after the last dose for methadone, and the first 24 hours may feel relatively normal for people stopping long-acting opioids. Early symptoms (hours 8-16 for short-acting): yawning, a classic early opioid withdrawal sign, runny nose and watery eyes, anxiety and restlessness, early muscle aches, and insomnia with an inability to get comfortable. Accelerating symptoms (hours 16-24): muscle aches and joint pain intensifying, nausea developing, sweating and chills, goosebumps (piloerection, which is why it's called 'cold turkey'), and significant anxiety and agitation. The neurochemical basis: opioids suppress the locus coeruleus, the brain's main norepinephrine-producing center, chronic suppression leads to upregulation of norepinephrine receptors, when opioids are removed, the locus coeruleus fires excessively, and this norepinephrine storm produces the autonomic symptoms of opioid withdrawal (sweating, racing heart, goosebumps, diarrhea). Medical urgency: opioid withdrawal is rarely fatal but profoundly uncomfortable, the risk of relapse during the first 24 hours is high, and tolerance is lost rapidly within days, meaning a relapse dose carries significant overdose risk.
What is the full opioid withdrawal timeline?
Opioid withdrawal follows a predictable timeline that varies by opioid type, with distinct phases that have different management needs. Short-acting opioids (heroin, oxycodone, hydrocodone): onset at 8-12 hours after last dose, peak symptoms at 36-72 hours, acute symptoms largely resolve by days 7-10, and PAWS can persist for weeks to months. Long-acting opioids (methadone): onset at 24-48 hours, slower build to peak, typically days 3-5, more prolonged acute withdrawal (2-3 weeks), and the prolonged withdrawal reflects methadone's very long half-life (24-36 hours). Fentanyl specifics: fentanyl has complex pharmacokinetics with rapid initial effects but accumulation in fat tissue, withdrawal can be unpredictable in onset and duration, and people withdrawing from illicit fentanyl, which often has adulterants, may experience additional complications. Phase breakdown: Days 1-3 (early acute): onset and escalation of withdrawal symptoms, anxiety, restlessness, muscle aches, yawning, runny nose. Days 3-7 (peak acute): peak physical symptoms, muscle cramps, insomnia, nausea, vomiting, diarrhea, profuse sweating. Days 7-14 (late acute): physical symptoms resolving, psychological symptoms (anxiety, depression, insomnia) persist, and cravings intensify as physical symptoms resolve. PAWS (weeks to months): the post-acute phase involves dysphoria, anxiety, insomnia, and cravings that can persist for 6 months or longer, this phase is when most relapses occur, and medication-assisted treatment significantly improves PAWS management.
Is opioid withdrawal dangerous?
Opioid withdrawal itself is rarely directly fatal in otherwise healthy adults, but it carries significant indirect dangers that make medical management important. The primary medical risks of withdrawal: severe dehydration from vomiting and diarrhea, particularly in people who cannot keep fluids down, electrolyte imbalances from dehydration, and in rare cases, cardiovascular stress in people with pre-existing heart conditions. Why deaths occur: death from opioid withdrawal most commonly occurs not from the withdrawal itself but from relapse during or shortly after withdrawal, when someone abstains from opioids, even briefly, their tolerance drops dramatically, a return to the previous dose after even a few days of abstinence can cause fatal respiratory depression, and this is the primary lethal risk associated with opioid withdrawal. The fentanyl complication: illicit fentanyl's variable potency makes relapse after tolerance loss particularly dangerous, even small amounts of fentanyl can cause overdose in someone who has lost tolerance, and this makes relapse prevention during and after withdrawal critically important. Special populations: pregnant women withdrawing from opioids face significant risks including preterm labor and fetal distress, opioid withdrawal in pregnancy should always be medically managed, typically with methadone or buprenorphine, and abrupt cessation in pregnancy is more dangerous than continuing opioid use with appropriate prenatal care. Who needs medical supervision: anyone who cannot stay hydrated due to vomiting, anyone with significant cardiac history, anyone with a history of severe mental health crises during withdrawal, pregnant women, and anyone without a safe, supportive environment for the withdrawal period.
What is medication-assisted treatment for opioid withdrawal?
Medication-assisted treatment (MAT) for opioid use disorder is the most evidence-supported approach to managing both withdrawal and long-term recovery, reducing overdose deaths, cravings, and relapse. Buprenorphine (Suboxone, Subutex): a partial opioid agonist that binds tightly to opioid receptors without producing significant euphoria at normal doses, eliminates withdrawal symptoms and cravings, Suboxone contains naloxone to deter injection, induction requires the patient to be in mild to moderate withdrawal before starting, and long-term maintenance is appropriate - there is no evidence that arbitrary time-limited treatment improves outcomes. Methadone: a full opioid agonist with a very long half-life (24-36 hours), eliminates withdrawal and cravings, dispensed at licensed opioid treatment programs (OTPs), particularly appropriate for people with severe use disorders who have not responded to other treatments, and decades of evidence support its use for long-term maintenance. Naltrexone (Vivitrol): an opioid antagonist that blocks the effects of opioids, must be started after complete opioid detox (7-10 days for short-acting, 10-14 days for methadone), does not prevent withdrawal but prevents opioid effects if relapse occurs, monthly injectable form (Vivitrol) improves adherence, and requires strong motivation as it provides no relief from PAWS symptoms. Clonidine: an alpha-2 adrenergic agonist that reduces the norepinephrine storm of opioid withdrawal, reduces autonomic symptoms (sweating, racing heart, anxiety, goosebumps), does not reduce cravings or prevent relapse, and is used as a symptom management tool rather than an addiction treatment. The evidence: MAT reduces opioid overdose mortality by 50-70%, reduces illicit opioid use, improves treatment retention, and produces better outcomes than withdrawal management alone.
What supplements and remedies help with opioid withdrawal?
Several supplements and supportive remedies have evidence or plausible mechanisms for easing opioid withdrawal symptoms, serving as useful adjuncts to medical management. For muscle aches and physical discomfort: NSAIDs (ibuprofen, naproxen) reduce inflammation-related pain, magnesium glycinate reduces muscle cramping and tension, hot baths and showers provide significant temporary relief, and heating pads for localized pain. For gastrointestinal symptoms: loperamide (Imodium) reduces diarrhea - the anti-diarrheal that does not cross the blood-brain barrier significantly at OTC doses, ginger tea for nausea, small frequent meals of bland food when appetite permits, and oral rehydration solutions to replace electrolytes lost through sweating and diarrhea. For sleep and anxiety: magnesium glycinate (400-800mg before bed) supports sleep and reduces muscle tension, melatonin (1-5mg) for sleep initiation, L-theanine has mild anxiolytic properties, and avoiding caffeine which worsens anxiety and disrupts sleep. For mood and energy: L-tyrosine (a dopamine precursor) in the morning to support energy, B vitamin complex for neurological support, omega-3 fatty acids for overall brain health, and vitamin C (high-dose protocols have been used in opioid detox, though evidence is limited). What the evidence supports most: clonidine (prescription) is the most evidence-supported non-opioid intervention for symptom management, over-the-counter symptom management (anti-diarrheal, pain reliever, antihistamine for sleep) combined with hydration and rest, and the supplements above have plausible mechanisms and low risk. Important note: none of these supplements meaningfully addresses the craving and addiction components of opioid withdrawal, they are supportive, not primary treatments.
How long does opioid withdrawal insomnia last?
Insomnia is one of the most persistent and distressing symptoms of opioid withdrawal, frequently lasting beyond the resolution of acute physical symptoms and affecting quality of life and relapse risk during recovery. Why opioids cause withdrawal insomnia: opioids have significant sleep-promoting effects through their action on opioid receptors, chronic use adapts the sleep system to opioid presence, withdrawal produces a hyperexcitable state (the norepinephrine storm) that is incompatible with sleep, and restless legs syndrome, extremely common in opioid withdrawal, specifically prevents the stillness needed for sleep initiation. Timeline for insomnia: insomnia begins with the onset of withdrawal symptoms, is typically worst in days 3-7 of acute withdrawal, begins improving as acute physical symptoms resolve, but often persists significantly into weeks 2-6, and in people experiencing PAWS, sleep disturbance can continue for months. The restless legs component: restless legs syndrome (RLS) is nearly universal in opioid withdrawal, the irresistible urge to move the legs, worsening at night, prevents sleep, magnesium, clonidine, and low-dose dopamine agonists (gabapentin, ropinirole) can help, and RLS typically resolves within weeks of abstinence. Managing withdrawal insomnia: sleep hygiene fundamentals are important, magnesium glycinate before bed, short-term antihistamines (diphenhydramine, doxylamine) for the first 1-2 weeks, clonidine (prescription) helps with the autonomic hyperexcitability, trazodone is used medically for longer-term sleep support, and avoiding long-term benzodiazepine use for sleep due to cross-dependence risks. When insomnia persists: sleep disturbance beyond 4-6 weeks of abstinence should be evaluated medically, underlying sleep disorders (sleep apnea, primary insomnia) may have been masked by opioid use, and treating co-occurring anxiety or depression typically improves persistent insomnia.
What is opioid PAWS and how do you manage it?
Post-Acute Withdrawal Syndrome (PAWS) from opioids is a prolonged neurological recovery process that is one of the primary drivers of relapse, affecting a significant proportion of people after completing acute opioid withdrawal. What opioid PAWS feels like: persistent dysphoria - a general state of unease and low mood, anhedonia (inability to experience normal pleasure), anxiety that can be episodic and intense, insomnia and sleep disturbance, fatigue and low motivation, cognitive difficulties including concentration and memory, and cravings that emerge episodically in response to stress, cues, or emotional states. The neurological basis: opioid receptors throughout the brain regulate mood, pain, reward, and stress response, chronic opioid use fundamentally alters these systems, the endogenous opioid system (which relies on the brain's own endorphins) recovers slowly after cessation, and PAWS symptoms reflect the brain functioning with depleted endogenous opioid tone during this recovery period. Timeline: PAWS symptoms typically begin as acute withdrawal resolves (week 2), are most intense in months 1-3, progressively improve through months 3-12, and may have intermittent episodes for up to 18-24 months in heavy, long-term users. Managing PAWS: medication-assisted treatment (buprenorphine or methadone) largely eliminates PAWS symptoms and is the most effective management strategy, for people not on MAT, aerobic exercise supports endogenous opioid system recovery, consistent sleep schedule, stress management techniques, ongoing peer support and counseling, and treating co-occurring depression or anxiety with appropriate medications. The relapse risk: PAWS is when most relapses occur because acute withdrawal has passed (removing the deterrent of feeling immediately sick) but the brain is not yet healed, and robust PAWS management is the most important factor for long-term recovery.
How does heroin withdrawal compare to prescription opioid withdrawal?
The comparison between heroin and prescription opioid withdrawal is important because while both involve opioid receptor withdrawal, there are meaningful differences in timeline, severity, and clinical context. Pharmacological similarities: heroin (diacetylmorphine) is a prodrug that rapidly converts to morphine, prescription opioids (oxycodone, hydrocodone, oxymorphone) have similar mechanisms, all produce withdrawal through the same fundamental mechanism (mu-opioid receptor adaptation and compensatory norepinephrine system upregulation), and the core symptom cluster is identical. Duration differences: heroin's short half-life means more frequent dosing and acute withdrawal beginning 8-12 hours after last dose, peaking at 36-60 hours, extended-release prescription opioids (OxyContin) have longer half-lives and slower onset of withdrawal, and this affects the withdrawal experience and taper strategies. Route of administration: heroin is typically injected, smoked, or insufflated, producing rapid intense peaks, this produces stronger conditioning and more intense withdrawal, prescription opioids are more often taken orally, producing slower onset and potentially less intense peak-related conditioning. Fentanyl complication: most heroin in the current drug supply contains fentanyl, fentanyl's complex pharmacokinetics (high fat solubility, redistribution from tissues) can make withdrawal onset and duration unpredictable, and what people call 'heroin withdrawal' is frequently fentanyl withdrawal with potentially different characteristics. Social context: prescription opioid dependence often develops in a medical context, heroin use typically involves additional social and contextual factors, and these contextual differences affect the recovery environment and social support available. Treatment access: both populations have access to MAT, but the social stigma and structural barriers differ, and prescription opioid users may have easier access to buprenorphine through primary care.
What does opioid recovery look like at 6 months?
Six months of opioid abstinence (or MAT-maintained recovery) represents a significant milestone, with measurable improvements across multiple domains. Physical recovery: the acute effects of opioids on the body have substantially resolved, liver function (often impaired by associated alcohol use or hepatitis from injection) is recovering, nutritional status, typically depleted during active use, has improved, and physical health conditions that were neglected during active use have had the opportunity for treatment. Neurological recovery: opioid receptor density has substantially normalized, the endogenous opioid system is recovering function, mood typically stabilizes significantly by 6 months, and cognitive function, particularly executive function, shows substantial improvement. What still requires attention at 6 months: PAWS symptoms may still be intermittently present, particularly in heavy, long-term users, cue-induced cravings can still occur and require management, and stress remains a significant relapse trigger. The emotional landscape: most people at 6 months describe feeling significantly better than during active withdrawal, the ability to experience normal pleasure has largely returned, emotional regulation is improved, and the sense of identity as a person in recovery is strengthening. Life domain improvements: relationships damaged during active use are in the process of repair, employment or education, if disrupted, is being reestablished, and the stability of 6 months of recovery allows for meaningful life rebuilding. The ongoing work: 6 months is not 'done' but is when ongoing recovery work - therapy, peer support, MAT continuation if applicable, life rebuilding - begins to show meaningful dividends, and the research is clear that longer engagement with recovery support correlates with better long-term outcomes.
Why do people relapse after opioid withdrawal?
Understanding the mechanisms of relapse after opioid withdrawal is essential for prevention, as relapse is the rule rather than the exception without adequate support - with 80-90% of people who complete withdrawal without treatment relapsing within a year. The tolerance loss problem: when opioids are stopped, tolerance (the dose required to produce effects) drops rapidly, within 3-7 days, tolerance can return toward pre-use levels, a person who relapses using their previous dose is at high risk of fatal overdose, and this is why the post-withdrawal period is so medically dangerous. PAWS-driven relapse: the persistent dysphoria, anxiety, insomnia, and anhedonia of PAWS make the promise of immediate opioid relief compelling, the contrast between how bad the person feels and how quickly opioids could relieve that feeling is a powerful driver of relapse, and PAWS management is therefore the most important relapse prevention priority. Cue-induced relapse: exposure to people, places, and paraphernalia associated with opioid use triggers conditioned craving, these cues remain powerful for months to years after cessation, and exposure to high-risk cues in early recovery is a major relapse trigger. Stress-induced relapse: acute stress activates the same neurological pathways as opioids, CRF (corticotropin-releasing factor) is released during stress and primes opioid cravings, and any significant life stressor (job loss, relationship conflict, health crisis) in early recovery is a high-risk period for relapse. What prevents relapse: medication-assisted treatment (buprenorphine, methadone) reduces relapse rates by 50-70% compared to abstinence-only approaches, ongoing counseling and peer support, managing PAWS symptoms, environmental changes that reduce cue exposure, and building a life with meaning and social connection that competes with opioid use as a coping strategy.
What are the long-term health effects of opioid use?
Long-term opioid use, particularly with illicit opioids and injection use, produces significant health consequences across multiple organ systems, many of which continue to require attention during recovery. Cardiovascular effects: infective endocarditis (heart valve infection) is a serious and potentially fatal consequence of injection drug use, peripheral vascular disease from needle use affects limb circulation, and myocardial disease can result from cocaine co-use or other cardiotoxic substances mixed with opioids. Liver disease: hepatitis C infection, highly prevalent in people who inject drugs, causes chronic liver inflammation and can progress to cirrhosis and liver cancer, hepatitis B is similarly transmitted, and alcoholic liver disease often co-occurs in people with opioid use disorder. Pulmonary disease: injection of non-sterile substances causes pulmonary emboli, heroin's respiratory depression effects can cause aspiration pneumonia, and smoking crack or heroin causes pulmonary damage. Infectious disease: HIV transmission through shared needles remains a significant risk, recurrent skin and soft tissue infections from injection, and systemic infections (osteomyelitis, septic arthritis) from bacteremia. Neurological effects: opioid-induced hyperalgesia - paradoxical increased pain sensitivity with chronic opioid use, cognitive impairment that partially recovers with abstinence, and the neurological consequences of hypoxia during overdoses. Endocrine effects: opioids suppress the hypothalamic-pituitary axis, hypogonadism (low testosterone in men, menstrual irregularity in women) is common, and bone density loss occurs with chronic opioid use. Recovery outlook: many of these consequences improve substantially with sustained abstinence and medical treatment, hepatitis C is now curable with direct-acting antivirals, HIV is manageable with antiretroviral therapy, and addressing these health conditions is an important part of comprehensive opioid recovery care.
What is the opioid withdrawal crash and how long does it last?
The opioid withdrawal crash describes the acute, intense period of withdrawal that occurs when opioids are abruptly stopped after regular use, characterized by a rapid reversal of all the effects opioids were producing. Why the crash occurs: opioids produce analgesia, euphoria, sedation, and suppression of the stress response, the brain adapts to these effects by reducing endogenous opioid production and downregulating opioid receptors, and when opioids are removed, the adapted brain is suddenly operating without both exogenous and endogenous opioid tone. Short-acting opioid crash (heroin, oxycodone, hydrocodone): begins 8-12 hours after last dose, escalates rapidly through hours 12-24, reaches peak intensity at 36-72 hours, the physical crash with its most severe symptoms lasts approximately 3-5 days, and by day 7, acute physical symptoms are largely resolving for most people. Fentanyl crash specifics: fentanyl has a short duration of action but high fat solubility and redistribution from tissue, the crash onset can be rapid (8-12 hours) but may have a complex course due to drug redistribution, and people withdrawing from illicit fentanyl sometimes experience fluctuating symptom severity as drug releases from fat stores. The psychological crash: depressed mood and anxiety during the crash are intense, the neurological state of acute opioid withdrawal is profoundly dysphoric, and this dysphoria, more than the physical symptoms, drives people to return to opioid use during the crash. Getting through the crash: medical management with clonidine significantly reduces autonomic symptoms, buprenorphine initiated during mild to moderate withdrawal eliminates symptoms, supportive care (hydration, symptom management) is critical, and having a supervised, safe environment prevents the access to opioids that would otherwise end the crash prematurely.
Track Every Day of Recovery
Forge tracks your streak, logs cravings, and marks recovery milestones as they hit, free on iPhone.
Download Free →Sources
- Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003, 35(2):253–259. PMID 12924748
- Koob GF, Volkow ND. Neurobiology of addiction. Lancet Psychiatry. 2016, 3(8):760–773. PMID 27475769
- SAMHSA. Treatment of Opioid Use Disorder (TIP 63). 2021. samhsa.gov